Home > Healthcare > Pharmaceuticals > Finished Drug Form > retinal biologics market
Get a free sample of Retinal Biologics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Retinal Biologics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The retinal biologics industry is characterized by the presence of leading pharmaceutical and biopharmaceutical companies. The key market players include F-Hoffman La Roche Ltd., Novartis AG, and AbbVie Inc. which are focused on developing improved treatments, such as longer-acting formulations and innovative therapies. Market players compete on factors like efficacy, safety, patient convenience, and cost-effectiveness.
Prominent players operating in the retinal biologics industry include:
AbbVie Inc., Amgen Inc., Janssen Pharmaceuticals (Johnson & Johnson), F-Hoffman La Roche Ltd., Oxurion NV, Novartis AG, MeiraGTx Limited, Regeneron Pharmaceuticals Inc., OncoGene Pharmaceuticals and SemaThera In
North America retinal biologics market was valued at USD 9.7 billion and is predicted to grow at 8% CAGR during 2024-2032, attributed to the advanced healthcare infrastructure and high prevalence of retinal diseases.
The macular degeneration segment held 40.1% of the market share in 2023 owing to the growing elderly population globally.
The global retinal biologics market was valued at USD 23.4 billion in 2023 and is anticipated grow at 8.2% CAGR during 2024-2032, attributed to the increasing prevalence of retinal diseases, particularly age-related macular degeneration (AMD) and diabetic retinopathy.